Recessive Dystrophic Epidermolysis Bullosa (RDEB) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Recessive Dystrophic Epidermolysis Bullosa Emerging Therapy and TPP Insights

Thelansis’s “Recessive Dystrophic Epidermolysis Bullosa (RDEB) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recessive Dystrophic Epidermolysis Bullosa Overview

Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin disorder caused by pathogenic variants in both copies of COL7A1, reducing or disrupting type VII collagen and the anchoring fibrils that bind skin layers. Minor friction can cause painful blisters, open wounds, scarring, and contractures; severe disease may affect the mouth and oesophagus and carries a high risk of aggressive cutaneous squamous cell carcinoma. Care includes protective wound dressings, pain and itch control, nutrition support, infection management, and regular skin-cancer surveillance. Treatment options now extend beyond supportive care. In the United States, topical gene therapy Vyjuvek treats wounds in dystrophic EB with COL7A1 variants, while Zevaskyn is an autologous gene-modified skin-cell sheet approved for RDEB wounds. Filsuvez is another option for wounds associated with RDEB. These treatments can help selected wounds heal but do not cure the disorder or remove the need for ongoing care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)